Verastem Oncology
Boston, United States · Biopharma, Biotechnology, Healthcare
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, includi
Key facts
- Headquarters
- Boston, United States
- Employees
- 106
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (VSTM)
- Website
- verastem.com
- Company page
Recent activity at Verastem Oncology
- : SEC 8-K (7.01): On December 29, 2025, Verastem, Inc. issued a press release announcing the discontinuation of the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). This decision was made after evaluating interim data, and the company will redirect resources towards the development of VS-7375, an oral KRAS G12D inhibitor, intended for advanced NSCLC and other solid tumors. No further patient enrollment in RAMP 203 will occur, although current participants may continue treatment at the discretion of their investigators. This strategic shift underscores the company's commitment to optimizing its portfolio in line with evolving clinical findings.
- : Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer
- : Verastem Oncology Licenses VS-7375, a New Oral KRAS G12D Inhibitor from GenFleet Therapeutics, and Shares Preliminary Clinical Data from Phase 1 Study in China.
- : Verastem Oncology Partners with Oberland Capital and IQVIA for Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian
- : Verastem Oncology Appoints John Hayslip, M.D. as Chief Medical Officer
- : Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
- : Verastem, Inc.
- : Verastem, Inc.
Verastem Oncology funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2020 | Venture | $100.0M |
| Jan 2020 | Seed | $4.8M |
Leadership
- GINA CONSYLMAN, Director
- BRUCE WENDEL, Director
- ERIC ROWINSKY, Director
- ALISON LAWTON, Director
- TIMOTHY BARBERICH, Director
- MICHAEL KAUFFMAN, Director
- BRIAN STUGLIK, Executive Officer, Director
- Matthew E. Ros, Chief Operating Officer
- John Hayslip, Chief Medical Officer
- Dan Paterson, President
- AMY CAVERS, Executive Officer
- CATHY CAREW, Executive Officer
Verified email and direct lines for Verastem Oncology’s decision-makers are on Fundz. See plans
Verastem Oncology in the news
- Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Business Wire (Aug 06, 2026)
- Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Yahoo Finance (Jul 23, 2026)
- Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers - Business Wire (Sep 08, 2026)
- Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire (Sep 24, 2026)
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Business Wire (May 07, 2026)
- Verastem Oncology to Participate in Upcoming September Investor Conferences - Yahoo Finance (Sep 02, 2026)
- Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire (May 12, 2026)
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Jul 02, 2026)
Companies similar to Verastem Oncology
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Therapeutics
About Verastem Oncology: questions and answers
What does Verastem Oncology do?
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, includi
Where is Verastem Oncology headquartered?
Verastem Oncology is headquartered in Boston, United States.
How many employees does Verastem Oncology have?
Verastem Oncology has about 106 employees.
Has Verastem Oncology raised funding?
Yes. Fundz has recorded 2 funding events for Verastem Oncology. The most recent, $100.0M, was in Mar 2020.
Who leads Verastem Oncology?
Dan Paterson is a President at Verastem Oncology.
What is the latest news on Verastem Oncology?
On Dec 29, 2025, SEC 8-K (7.01): On December 29, 2025, Verastem, Inc. issued a press release announcing the discontinuation of the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). This decision was made after evaluating interim data, and the company will redirect resources to
Is Verastem Oncology a public company?
Yes. Verastem Oncology is publicly traded under the ticker VSTM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy